Lustgarten Foundation Appoints David Tuveson, M.D., Ph.D., Chief Scientist
Dr. David Tuveson has been appointed the chief scientist for the Lustgarten Foundation. He specializes in pancreatic cancer reseach at the Cold Spring Harbor Labs.
Let’s Win Launches Online Video Series Featuring Long-Term Pancreatic Cancer Survivors
Meet long-term survivors of pancreatic cancers, in our new Survivors Video Series. The introductory video was launched in January at a cancer symposium.
Let’s Win and Partners Present Poster and Abstract at Gastrointestinal Cancer Symposium
"Introduction of #PancChat: A novel Twitter platform to inform and engage the pancreatic cancer community" at the 2018 Gastrointestinal Cancers…
New CancerSEEK Test Greater than 99 Percent Specific for Pancreatic Cancer
Dr. Anne Marie Lennon and colleagues have developed a blood screening test that can detect early cancer in eight organs, including the pancreas.
Keytruda Runner-up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
Lustgarten Foundation and Stand Up To Cancer Announce Two New Pancreatic Cancer Research Projects
The Lustgarten Foundation and Stand Up To Cancer announced the launch of two new pancreatic cancer interception research projects.
Faces of Let’s Win! Dr. David Tuveson
Dr. David Tuveson, MD, PhD, Director of the Lustgarten Foundation Pancreatic Research Laboratory at Cold Spring Harbor Laboratory, explains why pancreatic cancer is so difficult to treat.
Let’s Win! Inducted into the PR News Platinum Hall of Fame
On Thursday, September 14, Finn Partners announced that Let’s Win, an initiative supported by the Lustgarten Foundation, is being inducted…
New Study Shows Promising Results in the Development of More Effective Blood Test to Detect Pancreatic Cancer
The combination of ctDNA and protein markers was superior to any single marker alone. This work was funded in part…
New SU2C-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic Cancer
The approach is called chimeric antigen receptor (CAR) T-cell therapy, which uses specially modified immune cells to find and destroy…